Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Theo D. Kim"'
Autor:
Theo D. Kim, Philipp le Coutre, Michaela Schwarz, Peggy Grille, Michal Levitin, Suzanne Fateh-Moghadam, Francis J. Giles, Bernd Dörken, Wilhelm Haverkamp, Clemens Köhncke
Publikováno v:
Haematologica, Vol 97, Iss 6 (2012)
Background Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first- or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk of prolongation of the QT int
Externí odkaz:
https://doaj.org/article/faaa2a79922648c2a34b4de1f39982e8
Autor:
Theo D. Kim, Seval Türkmen, Michaela Schwarz, Gökben Koca, Hendrik Nogai, Christiane Bommer, Bernd Dörken, Peter Daniel, Philipp le Coutre
Publikováno v:
Haematologica, Vol 95, Iss 4 (2010)
Background Additional chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia are non-random and strongly associated with disease progression, but their prognostic impact and effect on treatment response is not clear. Poi
Externí odkaz:
https://doaj.org/article/c4a7292cc6db4fdebaad6db8e99ebaa6
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 212
With imatinib still being linked to the breakthrough in CML therapy and probably being the most prescribed drug, second-generation TKIs are increasingly gaining importance. Showing higher response rates while not leading to more adverse events, nilot
Publikováno v:
Small Molecules in Hematology ISBN: 9783319914381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a56881a2868643e83bcd548294306f
https://doi.org/10.1007/978-3-319-91439-8_3
https://doi.org/10.1007/978-3-319-91439-8_3
Autor:
Serge Leyvraz, Antonia Busse, Eric Blanc, Andreas Mock, Damian T. Rieke, Lutz Brinkmann, Peter Horak, Theo D. Kim, Sebastian Ochsenreither, Stefan Froehling, Mario Lamping, Ulrich Keilholz, Konrad Klinghammer, Inge Tinhofer, Clemens Messerschmidt, Frederick Klauschen, Antje Tessmer, Lars Fischer, Dieter Beule
Publikováno v:
Journal of Clinical Oncology. 37:e17577-e17577
e17577 Background: Salivary gland tumors (SGT) represent a rare and heterogeneous group of malignancies. No standard treatment exists in the advanced situation and the prognosis is poor. We here report characteristics and clinical outcomes of patient
Autor:
Wilhelm Haverkamp, Giovanni Rosti, H Labussière, Ruhdja Lindhorst, Theo-D. Kim, Bernd Dörken, P. le Coutre, Hervé Dombret, Francis J. Giles, Peggy Grille, Tristan Mirault, Michaela Schwarz, Delphine Rea, F. E. Nicolini, Luciano Levato, Ivo Buschmann
Publikováno v:
Leukemia. 27:1316-1321
Several retrospective studies have described the clinical manifestation of peripheral artery occlusive disease (PAOD) in patients receiving nilotinib. We thus prospectively screened for PAOD in patients with chronic phase chronic myeloid leukemia (CP
Autor:
Giovanni Rosti, Theo-D. Kim, J.L. Steegmann, Dong-Kee Kim, Massimo Breccia, Richard E. Clark, Michele Baccarani, Susanne Saussele, Kimmo Porkka, P. le Coutre, L.F. Casado, Jiří Mayer, Hanna Jean Khoury, Dragana Milojkovic, Valentín García-Gutiérrez, Delphine Rea, Ruediger Hehlmann, Andreas Hochhaus
Publikováno v:
LEUKEMIA
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Leukemia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Leukemia
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9d5248c9dd270e0c0dcc8b099cb874b
Autor:
Ulrich Schweizer, Jerome M. Hershman, Josef Köhrle, Theo D. Kim, Doreen Braun, Philipp le Coutre
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 97:E100-E105
Tyrosine kinase inhibitors (TKI) are used for the treatment of various cancers. Case reports and clinical trials have reported abnormal thyroid function tests (TFT) after treatment with sunitinib, imatinib, sorafenib, dasatinib, and nilotinib. An inc
Autor:
Kamran Movassaghi, Bernd Dörken, Karl-Anton Kreuzer, Theo D. Kim, Michaela Schwarz, Peggy Grille, Philipp le Coutre, Peter T. Daniel, Jaspal Kaeda
Publikováno v:
Leukemia & Lymphoma. 52:517-520
Based on the impressive results from the IRIS trial (International Randomized Interferon vs. STI-571), the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) has become the recommended first-li...
Autor:
Theo D. Kim, Philipp le Coutre
Publikováno v:
Expert Opinion on Drug Safety. 10:97-107
Several therapeutic options, including tyrosine kinase inhibitors, exist for the treatment of patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Despite impressive results, there is room for improvement for those pati